Pharming « Terug naar discussie overzicht

Radio Pharming !

Jager63
0
Pharming announces first patient enrolled in pediatric clinical trial of leniolisib
The multinational Phase III study is evaluating leniolisib tablets in children aged 4 to 11 years with APDS, a rare primary immunodeficiency

Leiden, The Netherlands, February 21, 2023
Pharming Group N.V. ("Pharming" or "the Company") (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces that the first patient has been enrolled in its Phase III clinical trial (NCT05438407) evaluating the investigational drug leniolisib, an oral, selective phosphoinositide 3-kinase delta (PI3Kd) inhibitor, in children with activated phosphoinositide 3-kinase delta syndrome (APDS). There is currently no approved treatment for this complex and progressive disease caused by genetic variants.
43.792 Posts, Pagina: « 1 2 3 4 5 6 ... 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 ... 2186 2187 2188 2189 2190 » | Laatste
Aantal posts per pagina:  20 50 100 | Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Detail

Vertraagd 10 mei 2024 17:35
Koers 0,882
Verschil +0,009 (+1,03%)
Hoog 0,893
Laag 0,869
Volume 6.382.235
Volume gemiddeld 6.784.015
Volume gisteren 5.197.921